Volume 5, Issue 1, March 2020, Page: 1-5
Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity
Ametov Alexander Sergeevich, Russian Medical Academy of Continuing Professional Education, Moscow, Russia
Gusenbekova Dinara Gadjimagomedovna, Russian Medical Academy of Continuing Professional Education, Moscow, Russia
Butaeva Svetlana Garrievna, Russian Medical Academy of Continuing Professional Education, Moscow, Russia
P'yanykh Olga Pavlovna, Russian Medical Academy of Continuing Professional Education, Moscow, Russia
Received: Nov. 23, 2019;       Accepted: Jan. 2, 2020;       Published: Jan. 9, 2020
DOI: 10.11648/j.ijde.20200501.11      View  357      Downloads  133
Abstract
Diabetes mellitus is one of the most common diseases of the endocrine system that is encountered in the practice of any doctor in any specialty. Some features of type 2 diabetes are: a slow progressive development and a mild clinical picture in the early stages of the development of the disease. The main goal of diabetes treatment is to prevent the development of late complications that reduce the quality of life of patients, leading to their early disability and death. Despite the increase in the number of antihyperglycemic drugs in the pharmaceutical industry, we are still not successful enough to achieve good glycemic control. In addition, achieving good glycemic control does not always prevent macrovascular complications in patients with diabetes mellitus. The article presents the results of two studies. The first study examined the diurnal fluctuations in blood glucose levels during therapy with type 4 dipeptidyl peptidase inhibitor Sitagliptin, as well as its effect on oxidative stress markers in comparison with MV gliclazide. The second study examined the role of sitagliptin in the correction of disorders of fat metabolism.
Keywords
Diabetes, Obesity, Sitagliptin, Fat Metabolism, Glucose Monitoring
To cite this article
Ametov Alexander Sergeevich, Gusenbekova Dinara Gadjimagomedovna, Butaeva Svetlana Garrievna, P'yanykh Olga Pavlovna, Possibilities of Early Combination Therapy with Sitagliptin and Metformin in the Correction of Metabolic Disorders in Patients with Type 2 Diabetes and Obesity, International Journal of Diabetes and Endocrinology. Vol. 5, No. 1, 2020, pp. 1-5. doi: 10.11648/j.ijde.20200501.11
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Nathan R. Hill, DPhil, Nick S. Oliver, Pratik Choudhary. Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups. Diabetes technology & therapeutics. 2011 Sep; 13 (9): 921–928. doi: 10.1089/dia.2010.0247.
[2]
Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M. Plasma glucose levels throughout the day and HbA (1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001. Vol. 24. № 12. P. 2023–2029. doi.org/10.2337/diacare.24.12.2023.
[3]
Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011 May; 34 Suppl. 2: S120-7. doi: 10.2337/dc11-s206.
[4]
Kashiwagi AL, Asahina T, Nishio Y. Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes. 1996 Jul; 45 Suppl. 3: S84-6.doi: https://www.ncbi.nlm.nih.gov/pubmed/8674901.
[5]
Tonooka N, Oseid E, Zhou H, Harmon JS, Robertson RP. Glutathione peroxidase protein expression and activity in human islets isolated for transplantation. Clinical Transplantation. 2007 Nov-Dec; 21 (6): 767-72. doi 10.1111/j.1399-0012.2007.00736.x.
[6]
Pankratova MA, Pirozhkov SV, Balabolkin MI, Litvicki PF. Oxidative stress in patients with type 2 diabetes mellitus with different duration of the disease and varying degrees of compensation for carbohydrate metabolism. Diabetes mellitus. 2/2006, P. 12-15. doi: http://dx.doi.org/10.14341/2072-0351-6113.
[7]
Van Genugten R. Moller-Goede D., van Raatle D. et al Extrapancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes / Diabetes, Obesity and Metabolism-2013-№7: 593606.
[8]
Jose T. Inzucchi S. Cardiovascular effects of the DPP-4 inhibitors. Diabetes and Vascular Disease Research-2012№2: 109-116.
[9]
Satoh-Asahara N. Sasaki Y., Wada H. et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism-2013-№3: 347351.
[10]
Derosa G. Ragonesi P., Fogaria E. at al. Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. Fundam Clin Pharmacol-2012-№2: 221-229.
[11]
Nomura K, Saitoh T, Kim GU et al. Glycemic Profiles of Healthy Individuals with Low Fasting Plasma Glucose and HbA1c. ISRN Endocrinology. Volume 2011 (2011), Article ID 435047, 6 pages http://dx.doi.org/10.5402/2011/435047.
[12]
Ametov A. S., Gusenbekova D. G. The role of DPP-4 inhibitors in the correction of fat metabolism disorders in patients with type 2 diabetes and obesity. Diabetes mellitus. 2015; 18 (3): 8592.
[13]
https://www.intechopen.com/books/diabetes-and-its-complications/dpp-4-inhibitors-and-fatmetabolism-in-patients-with-type-2-diabetes.
[14]
Ametov A. S., Gusenbekova D. G. International Journal of Clinical and Experimental Medical Sciences. Volume 4, Issue 6, November 2018, Pages: 78-86.
[15]
Hill NR, Nick SO, Choudhary P et al. Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups Diabetes// Technology & Therapeutics. August 2011, 13 (9): 921-928. doi: 10.1089/dia.2010.0247.
[16]
O’Brien R. C, Luo M, Balazs N. et al. In-vitro and in-vivo antioxidant properties of gliclazide. Journal of Diabetes and its Complications. 2000. Vol. 14. P. 201–206 doi: http://dx.doi.org/10.1016/S1056-8727(00)00084-2.
[17]
Pocai A., Carrington P., Adams J., et al. Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice. Diabetes.-№10-2009: 2258–2266.
[18]
Kim Ch., Hosaka T., Yoshida M. et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochemical and Biophysical Research Communications - 2009-№3: 613–618.
[19]
Nomura Sh., Omoto S., Taniura T. et al. Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - 2015: 339.
[20]
Nagao H., Kashine S., Nishizawa H., et al. Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovascular Diabetology - 2013-№1: 88.
Browse journals by subject